Early occurrence of inspiratory muscle ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Early occurrence of inspiratory muscle weakness in parkinson''s disease
Author(s) :
Baille, Guillaume [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Perez, Thierry [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Devos, David [Auteur]
451074|||Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV] (OLD)
Deken, Valerie [Auteur]
Service de Biostatistiques [CHRU Lille]
Defebvre, Luc [Auteur]
451074|||Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV] (OLD)
Moreau, caroline [Auteur]
451074|||Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV] (OLD)
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Perez, Thierry [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Devos, David [Auteur]
451074|||Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV] (OLD)
Deken, Valerie [Auteur]
Service de Biostatistiques [CHRU Lille]
Defebvre, Luc [Auteur]
451074|||Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV] (OLD)
Moreau, caroline [Auteur]
451074|||Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV] (OLD)
Journal title :
PLoS One
Abbreviated title :
PLoS One
Volume number :
13
Pages :
e0190400
Publication date :
2018-01-12
ISSN :
1932-6203
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
In Parkinson's disease (PD), respiratory insufficiency (including functional and muscle disorders) can impact dysarthria and swallowing. Most studies of this topic have been performed retrospectively in populations of ...
Show more >In Parkinson's disease (PD), respiratory insufficiency (including functional and muscle disorders) can impact dysarthria and swallowing. Most studies of this topic have been performed retrospectively in populations of patients with advanced PD. The objective of the present study was to characterize lung function (under off-drug conditions) in early-stage PD patients at baseline and then again two years later. Forty-one early-stage PD patients (mean ± SD age: 61.7 ± 7.7; mean ± SD disease duration: 1.9 ± 1.7 years) were prospectively enrolled and compared with 36 age-matched healthy controls. Neurological evaluations and pulmonary function testing were performed in the off-drug condition at the inclusion visit and then two years later. Pulmonary function testing did not reveal any restrictive or obstructive disorders; at baseline, inspiratory muscle weakness was the only abnormality observed in the PD group (in 53.7% of the patients, vs. 25% in controls; p = 0.0105). The PD patients had a lower mean maximal inspiratory mouth pressure than controls and a lower sniff nasal inspiratory pressure. Two years after the initiation of chronic treatment with antiparkinsonian medications, the maximal inspiratory mouth pressure and the sniff nasal inspiratory pressure tended to be higher. Lastly, overall motor outcomes were not significantly worse in patients with inspiratory muscle weakness than in patients without inspiratory muscle weakness. Inspiratory muscle weakness seems to be common in patients with early-stage PD, and was seen to be stable over a two-year period. Additional long-term follow-up studies are required to specify the impact of this new feature of PD.Show less >
Show more >In Parkinson's disease (PD), respiratory insufficiency (including functional and muscle disorders) can impact dysarthria and swallowing. Most studies of this topic have been performed retrospectively in populations of patients with advanced PD. The objective of the present study was to characterize lung function (under off-drug conditions) in early-stage PD patients at baseline and then again two years later. Forty-one early-stage PD patients (mean ± SD age: 61.7 ± 7.7; mean ± SD disease duration: 1.9 ± 1.7 years) were prospectively enrolled and compared with 36 age-matched healthy controls. Neurological evaluations and pulmonary function testing were performed in the off-drug condition at the inclusion visit and then two years later. Pulmonary function testing did not reveal any restrictive or obstructive disorders; at baseline, inspiratory muscle weakness was the only abnormality observed in the PD group (in 53.7% of the patients, vs. 25% in controls; p = 0.0105). The PD patients had a lower mean maximal inspiratory mouth pressure than controls and a lower sniff nasal inspiratory pressure. Two years after the initiation of chronic treatment with antiparkinsonian medications, the maximal inspiratory mouth pressure and the sniff nasal inspiratory pressure tended to be higher. Lastly, overall motor outcomes were not significantly worse in patients with inspiratory muscle weakness than in patients without inspiratory muscle weakness. Inspiratory muscle weakness seems to be common in patients with early-stage PD, and was seen to be stable over a two-year period. Additional long-term follow-up studies are required to specify the impact of this new feature of PD.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
CNRS
Inserm
Institut Pasteur de Lille
Université de Lille
CNRS
Inserm
Institut Pasteur de Lille
Université de Lille
Submission date :
2019-11-27T13:04:16Z
2024-03-27T10:27:45Z
2024-03-27T10:27:45Z
Files
- file.pdf
- Non spécifié
- Open access
- Access the document
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States